Real‐world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis. Issue 7 (23rd April 2022)

• Record Type: Journal Article
• Authors: Suehiro, Masataka; Numata, Tomofumi; Murakami, Emi; Takahashi, Masakazu; Saito, Ryo; Morioke, Satoshi; Kamegashira, Akiko; Takahagi, Shunsuke; Hide, Michihiro; Tanaka, Akio
• Is Part Of: Dermatologic therapy. Volume 35:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-04-23
• Subjects: atopic dermatitis -- corticosteroid -- delgocitinib -- JAK inhibitor -- stratum corneum hydration; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.15526
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Previous studies have shown the efficacy of delgocitinib (DEL) ointment, a topical Janus kinase inhibitor, against atopic dermatitis (AD). However, there is no available information regarding the efficacy of DEL ointment in maintaining remission. Data of patients with AD who received remission maintenance therapy twice weekly with DEL or topical corticosteroid (TCS) on the affected skin of each upper limb were extracted from the medical records. Efficacy was assessed based on changes in pruritus numerical rating scale (NRS) score, stratum corneum hydration (SCH), erythema index (EI). Of 25 patients, four patients (16%) had eczema flare‐ups on the TCS side and eight patients (32%) on the DEL side. The extent of change in each parameter between TCS‐ and DEL‐treated areas of the skin did not differ significantly. The mean changes in the NRS and EI showed a slight improvement on the side treated with TCS and were slightly worse on the side treated with DEL. However, the SCH of the DEL group was maintained, while that of the TCS group worsened. TCS is more likely to be effective than DEL in terms of remission maintenance therapy. However, topical DEL is as effective as topical steroid in the maintenance therapy of AD in dry skin patients.